Table of Contents Chapter 1 Overview of Immune Thrombocytopenic Purpura Therapeutics 1.1 Definition of Immune Thrombocytopenic Purpura Therapeutics in This Report 1.2 Commercial Types of Immune Thrombocytopenic Purpura Therapeutics 1.2.1 Eltrombopag Olamine 1.2.2 Fostamatinib Disodium 1.2.3 GL-2045 1.2.4 Avatrombopag 1.2.5 BI-655064 1.2.6 Others 1.3 Downstream Application of Immune Thrombocytopenic Purpura Therapeutics 1.3.1 Hospital 1.3.2 Clinic 1.3.3 Others 1.4 Development History of Immune Thrombocytopenic Purpura Therapeutics 1.5 Market Status and Trend of Immune Thrombocytopenic Purpura Therapeutics 2013-2023 1.5.1 Global Immune Thrombocytopenic Purpura Therapeutics Market Status and Trend 2013-2023 1.5.2 Regional Immune Thrombocytopenic Purpura Therapeutics Market Status and Trend 2013-2023 Chapter 2 Global Market Status and Forecast by Regions 2.1 Market Development of Immune Thrombocytopenic Purpura Therapeutics 2013-2017 2.2 Production Market of Immune Thrombocytopenic Purpura Therapeutics by Regions 2.2.1 Production Volume of Immune Thrombocytopenic Purpura Therapeutics by Regions 2.2.2 Production Value of Immune Thrombocytopenic Purpura Therapeutics by Regions 2.3 Demand Market of Immune Thrombocytopenic Purpura Therapeutics by Regions 2.4 Production and Demand Status of Immune Thrombocytopenic Purpura Therapeutics by Regions 2.4.1 Production and Demand Status of Immune Thrombocytopenic Purpura Therapeutics by Regions 2013-2017 2.4.2 Import and Export Status of Immune Thrombocytopenic Purpura Therapeutics by Regions 2013-2017 Chapter 3 Global Market Status and Forecast by Types 3.1 Production Volume of Immune Thrombocytopenic Purpura Therapeutics by Types 3.2 Production Value of Immune Thrombocytopenic Purpura Therapeutics by Types 3.3 Market Forecast of Immune Thrombocytopenic Purpura Therapeutics by Types Chapter 4 Global Market Status and Forecast by Downstream Industry 4.1 Demand Volume of Immune Thrombocytopenic Purpura Therapeutics by Downstream Industry 4.2 Market Forecast of Immune Thrombocytopenic Purpura Therapeutics by Downstream Industry Chapter 5 Market Driving Factor Analysis of Immune Thrombocytopenic Purpura Therapeutics 5.1 Global Economy Situation and Trend Overview 5.2 Immune Thrombocytopenic Purpura Therapeutics Downstream Industry Situation and Trend Overview Chapter 6 Immune Thrombocytopenic Purpura Therapeutics Market Competition Status by Major Manufacturers 6.1 Production Volume of Immune Thrombocytopenic Purpura Therapeutics by Major Manufacturers 6.2 Production Value of Immune Thrombocytopenic Purpura Therapeutics by Major Manufacturers 6.3 Basic Information of Immune Thrombocytopenic Purpura Therapeutics by Major Manufacturers 6.3.1 Headquarters Location and Established Time of Immune Thrombocytopenic Purpura Therapeutics Major Manufacturer 6.3.2 Employees and Revenue Level of Immune Thrombocytopenic Purpura Therapeutics Major Manufacturer 6.4 Market Competition News and Trend 6.4.1 Merger, Consolidation or Acquisition News 6.4.2 Investment or Disinvestment News 6.4.3 New Product Development and Launch Chapter 7 Immune Thrombocytopenic Purpura Therapeutics Major Manufacturers Introduction and Market Data 7.1 Amgen Inc. 7.1.1 Company profile 7.1.2 Representative Immune Thrombocytopenic Purpura Therapeutics Product 7.1.3 Immune Thrombocytopenic Purpura Therapeutics Sales, Revenue, Price and Gross Margin of Amgen Inc. 7.2 Baxalta Incorporated 7.2.1 Company profile 7.2.2 Representative Immune Thrombocytopenic Purpura Therapeutics Product 7.2.3 Immune Thrombocytopenic Purpura Therapeutics Sales, Revenue, Price and Gross Margin of Baxalta Incorporated 7.3 Boehringer Ingelheim GmbH 7.3.1 Company profile 7.3.2 Representative Immune Thrombocytopenic Purpura Therapeutics Product 7.3.3 Immune Thrombocytopenic Purpura Therapeutics Sales, Revenue, Price and Gross Margin of Boehringer Ingelheim GmbH 7.4 Bristol-Myers Squibb Company 7.4.1 Company profile 7.4.2 Representative Immune Thrombocytopenic Purpura Therapeutics Product 7.4.3 Immune Thrombocytopenic Purpura Therapeutics Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb Company 7.5 Eisai 7.5.1 Company profile 7.5.2 Representative Immune Thrombocytopenic Purpura Therapeutics Product 7.5.3 Immune Thrombocytopenic Purpura Therapeutics Sales, Revenue, Price and Gross Margin of Eisai 7.6 Hansa Medical AB 7.6.1 Company profile 7.6.2 Representative Immune Thrombocytopenic Purpura Therapeutics Product 7.6.3 Immune Thrombocytopenic Purpura Therapeutics Sales, Revenue, Price and Gross Margin of Hansa Medical AB 7.7 Immunomedics, Inc. 7.7.1 Company profile 7.7.2 Representative Immune Thrombocytopenic Purpura Therapeutics Product 7.7.3 Immune Thrombocytopenic Purpura Therapeutics Sales, Revenue, Price and Gross Margin of Immunomedics, Inc. 7.8 Intas Pharmaceuticals Ltd. 7.8.1 Company profile 7.8.2 Representative Immune Thrombocytopenic Purpura Therapeutics Product 7.8.3 Immune Thrombocytopenic Purpura Therapeutics Sales, Revenue, Price and Gross Margin of Intas Pharmaceuticals Ltd. 7.9 Jiangsu Hengrui Medicine Co., Ltd. 7.9.1 Company profile 7.9.2 Representative Immune Thrombocytopenic Purpura Therapeutics Product 7.9.3 Immune Thrombocytopenic Purpura Therapeutics Sales, Revenue, Price and Gross Margin of Jiangsu Hengrui Medicine Co., Ltd. 7.10 Merck & Co., Inc. 7.10.1 Company profile 7.10.2 Representative Immune Thrombocytopenic Purpura Therapeutics Product 7.10.3 Immune Thrombocytopenic Purpura Therapeutics Sales, Revenue, Price and Gross Margin of Merck & Co., Inc. 7.11 Momenta Pharmaceuticals, Inc. 7.11.1 Company profile 7.11.2 Representative Immune Thrombocytopenic Purpura Therapeutics Product 7.11.3 Immune Thrombocytopenic Purpura Therapeutics Sales, Revenue, Price and Gross Margin of Momenta Pharmaceuticals, Inc. 7.12 Novartis AG 7.12.1 Company profile 7.12.2 Representative Immune Thrombocytopenic Purpura Therapeutics Product 7.12.3 Immune Thrombocytopenic Purpura Therapeutics Sales, Revenue, Price and Gross Margin of Novartis AG 7.13 Pfizer Inc. 7.13.1 Company profile 7.13.2 Representative Immune Thrombocytopenic Purpura Therapeutics Product 7.13.3 Immune Thrombocytopenic Purpura Therapeutics Sales, Revenue, Price and Gross Margin of Pfizer Inc. Chapter 8 Upstream and Downstream Market Analysis of Immune Thrombocytopenic Purpura Therapeutics 8.1 Industry Chain of Immune Thrombocytopenic Purpura Therapeutics 8.2 Upstream Market and Representative Companies Analysis 8.3 Downstream Market and Representative Companies Analysis Chapter 9 Cost and Gross Margin Analysis of Immune Thrombocytopenic Purpura Therapeutics 9.1 Cost Structure Analysis of Immune Thrombocytopenic Purpura Therapeutics 9.2 Raw Materials Cost Analysis of Immune Thrombocytopenic Purpura Therapeutics 9.3 Labor Cost Analysis of Immune Thrombocytopenic Purpura Therapeutics 9.4 Manufacturing Expenses Analysis of Immune Thrombocytopenic Purpura Therapeutics Chapter 10 Marketing Status Analysis of Immune Thrombocytopenic Purpura Therapeutics 10.1 Marketing Channel 10.1.1 Direct Marketing 10.1.2 Indirect Marketing 10.1.3 Marketing Channel Development Trend 10.2 Market Positioning 10.2.1 Pricing Strategy 10.2.2 Brand Strategy 10.2.3 Target Client 10.3 Distributors/Traders List Chapter 11 Report Conclusion Chapter 12 Research Methodology and Reference 12.1 Methodology/Research Approach 12.1.1 Research Programs/Design 12.1.2 Market Size Estimation 12.1.3 Market Breakdown and Data Triangulation 12.2 Data Source 12.2.1 Secondary Sources 12.2.2 Primary Sources 12.3 Reference

List of Tables Table Advantage and Disadvantage of Eltrombopag Olamine Table Advantage and Disadvantage of Fostamatinib Disodium Table Advantage and Disadvantage of GL-2045 Table Advantage and Disadvantage of Avatrombopag Table Advantage and Disadvantage of BI-655064 Table Advantage and Disadvantage of Others Table Production Volume of Immune Thrombocytopenic Purpura Therapeutics by Regions 2013-2017 Table Production Value of Immune Thrombocytopenic Purpura Therapeutics by Regions 2013-2017 Table Demand Volume of Immune Thrombocytopenic Purpura Therapeutics by Regions 2013-2017 Table Production and Demand Status of Immune Thrombocytopenic Purpura Therapeutics in Region One 2013-2017 Table Production and Demand Status of Immune Thrombocytopenic Purpura Therapeutics in Region Two 2013-2017 Table Production and Demand Status of Immune Thrombocytopenic Purpura Therapeutics in Region Three 2013-2017 Table Production and Demand Status of Immune Thrombocytopenic Purpura Therapeutics in Region Four 2013-2017 Table Import Volume of Immune Thrombocytopenic Purpura Therapeutics by Regions 2013-2017 Table Export Volume of Immune Thrombocytopenic Purpura Therapeutics by Regions 2013-2017 Table Production Volume of Immune Thrombocytopenic Purpura Therapeutics by Types 2013-2017 Table Production Value of Immune Thrombocytopenic Purpura Therapeutics by Types 2013-2017 Table Production Volume Forecast of Immune Thrombocytopenic Purpura Therapeutics by Types 2018-2023 Table Production Value Forecast of Immune Thrombocytopenic Purpura Therapeutics by Types 2018-2023 Table Demand Volume of Immune Thrombocytopenic Purpura Therapeutics by Downstream Industry 2013-2017 Table Demand Volume Forecast of Immune Thrombocytopenic Purpura Therapeutics by Downstream Industry 2018-2023 Table Production Volume of Immune Thrombocytopenic Purpura Therapeutics by Major Manufacturers 2013-2017 Table Production Value of Immune Thrombocytopenic Purpura Therapeutics by Major Manufacturers 2013-2017 Table Headquarters Location and Established Time of Immune Thrombocytopenic Purpura Therapeutics Major Manufacturer Table Employees and Revenue Level of Immune Thrombocytopenic Purpura Therapeutics Major Manufacturer Table Representative Immune Thrombocytopenic Purpura Therapeutics Product One of Amgen Inc. Table Representative Immune Thrombocytopenic Purpura Therapeutics Product Two of Amgen Inc. Table Immune Thrombocytopenic Purpura Therapeutics Sales, Revenue, Price and Gross Margin of Amgen Inc. 2013-2017 Table Representative Immune Thrombocytopenic Purpura Therapeutics Product One of Baxalta Incorporated Table Representative Immune Thrombocytopenic Purpura Therapeutics Product Two of Baxalta Incorporated Table Immune Thrombocytopenic Purpura Therapeutics Sales, Revenue, Price and Gross Margin of Baxalta Incorporated 2013-2017 Table Representative Immune Thrombocytopenic Purpura Therapeutics Product One of Boehringer Ingelheim GmbH Table Representative Immune Thrombocytopenic Purpura Therapeutics Product Two of Boehringer Ingelheim GmbH Table Immune Thrombocytopenic Purpura Therapeutics Sales, Revenue, Price and Gross Margin of Boehringer Ingelheim GmbH 2013-2017 Table Representative Immune Thrombocytopenic Purpura Therapeutics Product One of Bristol-Myers Squibb Company Table Representative Immune Thrombocytopenic Purpura Therapeutics Product Two of Bristol-Myers Squibb Company Table Immune Thrombocytopenic Purpura Therapeutics Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb Company 2013-2017 Table Representative Immune Thrombocytopenic Purpura Therapeutics Product One of Eisai Table Representative Immune Thrombocytopenic Purpura Therapeutics Product Two of Eisai Table Immune Thrombocytopenic Purpura Therapeutics Sales, Revenue, Price and Gross Margin of Eisai 2013-2017 Table Representative Immune Thrombocytopenic Purpura Therapeutics Product One of Hansa Medical AB Table Representative Immune Thrombocytopenic Purpura Therapeutics Product Two of Hansa Medical AB Table Immune Thrombocytopenic Purpura Therapeutics Sales, Revenue, Price and Gross Margin of Hansa Medical AB 2013-2017 Table Representative Immune Thrombocytopenic Purpura Therapeutics Product One of Immunomedics, Inc. Table Representative Immune Thrombocytopenic Purpura Therapeutics Product Two of Immunomedics, Inc. Table Immune Thrombocytopenic Purpura Therapeutics Sales, Revenue, Price and Gross Margin of Immunomedics, Inc. 2013-2017 Table Representative Immune Thrombocytopenic Purpura Therapeutics Product One of Intas Pharmaceuticals Ltd. Table Representative Immune Thrombocytopenic Purpura Therapeutics Product Two of Intas Pharmaceuticals Ltd. Table Immune Thrombocytopenic Purpura Therapeutics Sales, Revenue, Price and Gross Margin of Intas Pharmaceuticals Ltd. 2013-2017 Table Representative Immune Thrombocytopenic Purpura Therapeutics Product One of Jiangsu Hengrui Medicine Co., Ltd. Table Representative Immune Thrombocytopenic Purpura Therapeutics Product Two of Jiangsu Hengrui Medicine Co., Ltd. Table Immune Thrombocytopenic Purpura Therapeutics Sales, Revenue, Price and Gross Margin of Jiangsu Hengrui Medicine Co., Ltd. 2013-2017 Table Representative Immune Thrombocytopenic Purpura Therapeutics Product One of Merck & Co., Inc. Table Representative Immune Thrombocytopenic Purpura Therapeutics Product Two of Merck & Co., Inc. Table Immune Thrombocytopenic Purpura Therapeutics Sales, Revenue, Price and Gross Margin of Merck & Co., Inc. 2013-2017 Table Representative Immune Thrombocytopenic Purpura Therapeutics Product One of Momenta Pharmaceuticals, Inc. Table Representative Immune Thrombocytopenic Purpura Therapeutics Product Two of Momenta Pharmaceuticals, Inc. Table Immune Thrombocytopenic Purpura Therapeutics Sales, Revenue, Price and Gross Margin of Momenta Pharmaceuticals, Inc. 2013-2017 Table Representative Immune Thrombocytopenic Purpura Therapeutics Product One of Novartis AG Table Representative Immune Thrombocytopenic Purpura Therapeutics Product Two of Novartis AG Table Immune Thrombocytopenic Purpura Therapeutics Sales, Revenue, Price and Gross Margin of Novartis AG 2013-2017 Table Representative Immune Thrombocytopenic Purpura Therapeutics Product One of Pfizer Inc. Table Representative Immune Thrombocytopenic Purpura Therapeutics Product Two of Pfizer Inc. Table Immune Thrombocytopenic Purpura Therapeutics Sales, Revenue, Price and Gross Margin of Pfizer Inc. 2013-2017